KHRNF - Khiron Life Sciences Corp.
| Previous Close | 0.8179 |
| Open | 0.8100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.7980 - 0.8471 |
| 52 Week Range | 0.5919 - 3.2800 |
| Volume | 119,286 |
| Avg. Volume | 178,322 |
| Market Cap | 94.378M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3020 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupKhiron Increases Clinical Capacity in Colombia by 75% with Opening of Zerenia Integrated Medical Clinic
Khiron Increases Clinical Capacity in Colombia by 75% with Opening of Zerenia Integrated Medical Clinic
- Simply Wall St.
Have Insiders Been Buying Khiron Life Sciences Corp. (CVE:KHRN) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- CNW Group
Khiron CEO Alvaro Torres to Present at AltaCorp/ATB 8th Annual Institutional Investor Conference
TORONTO, Jan. 6, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that CEO and Director Alvaro Torres will speak on the International Expansion panel at the AltaCorp/ATB 8th Annual Institutional Investor Conference at 3:10pm on January 14, 2020. Mr. Torres and other members of the Khiron leadership team will also be conducting one-on-one meetings at the conference, taking place January 14-16, 2020 at the Shangri-La Hotel Toronto.
- Baystreet
Stocks in play: Khiron Life Sciences Corp.
Welcomes the Colombian government's announcement that the country has been awarded a record high quota ...
- CNW Group
Khiron Welcomes Colombia's Receipt of 2020 Production Quota of 56.5 Tons of High-THC Cannabis
Khiron the only LP with a 2019 quota that authorizes the Company to manufacture high-THC whole plant extract and produce customized medical cannabis prescriptions for domestic use 56.5 tons, or 21.84% ...
- CNW Group
Khiron Welcomes Regulatory Guidelines in Peru, Announces Good Storage Practices Certification
Khiron Welcomes Regulatory Guidelines in Peru, Announces Good Storage Practices Certification
- CNW Group
Khiron Welcomes Legalization of Medical Cannabis in Brazil
Khiron Welcomes Legalization of Medical Cannabis in Brazil
- CNW Group
Khiron Announces Chairman Transition and Appointment of Audit Committee Chair
TORONTO , Nov. 29, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , today announced that Sidney Himmel has resigned as Director and Chair of the Board to pursue other interests, effective immediately. "On behalf of my fellow directors, the Company's management team, and shareholders we thank Sid for his many contributions to Khiron since its founding," said Alvaro Torres , Khiron's CEO and Director.
- Simply Wall St.
We Think Khiron Life Sciences (CVE:KHRN) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- CNW Group
Khiron Announces Option and Restricted Share Unit Grants
Khiron Announces Option and Restricted Share Unit Grants
- CNW Group
Khiron Reports Q3 Fiscal 2019 Financial Results, With $47.9 Million Cash Balance and $2.8 Million in Quarterly Revenue
22 cannabis strains registered in Colombia and in Q3 successfully harvested a number of these strains, converting to an extract. TORONTO, Nov. 26, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America announced today its financial results for the third quarter ended September 30, 2019.
- Market Exclusive
Khiron Becomes First Colombian Firm to Commercialize THC Cannabis
Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) has received approval for commercial production of psychoactive, high-THC cannabis for both domestic and export purposes. The Colombian Technical Quotas Group (TQG) has authorized the company to cultivate and commercialize up to 560 kg or approximately, 65,000 units of psychoactive, high-THC cannabis in 2019. The authorization makes Khiron the first […]The post Khiron Becomes First Colombian Firm to Commercialize THC Cannabis appeared first on Market Exclusive.
- CNW Group
Khiron Receives First Colombian Authorization to Commercialize High-THC Cannabis for Domestic and Export Sales
TORONTO , Nov. 25, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , today announced that it has become the first and to date, only cannabis company in Colombia authorized to commercialize psychoactive, high-THC cannabis for both domestic and export purposes. Representing a key milestone towards Khiron's stated timeline to bring medical cannabis options to market, the authorization comes as a result of commercial quotas allocated to Khiron by the Colombian Technical Quotas Group ("TQG"), which permit the Company to cultivate and commercialize up to 560 kg – or approximately, 65,000 units – of psychoactive, high-THC cannabis in 2019.
- CNW Group
Khiron Director and 55th President of Mexico, Vicente Fox to Present Keynote at UK Cannabis Investor Conference
TORONTO , Nov. 21, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , today announced that Company Director and 55th President of Mexico , Vicente Fox , will present a keynote address at the Bryan, Garnier & Co Cannabis Conference, taking place on Thursday, November 28, 2019 in London, UK .
- CNW Group
Khiron to be Exclusive Latin American Provider to Project Twenty21, Europe's Largest Medical Cannabis Study with 20,000 Patients
Khiron Life Sciences establishes early mover position to build its brand and product offering in the United Kingdom's nascent medical cannabis market Project Twenty21 will study medical cannabis's therapeutic ...
